StockNews.com Initiates Coverage on Aptose Biosciences (NASDAQ:APTO)

StockNews.com assumed coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report published on Friday. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and issued a $2.00 price target on shares of Aptose Biosciences in a research note on Friday, January 10th.

Aptose Biosciences Trading Up 3.7 %

Shares of NASDAQ:APTO opened at $0.21 on Friday. The stock has a fifty day simple moving average of $0.22 and a two-hundred day simple moving average of $0.37. The stock has a market capitalization of $12.82 million, a price-to-earnings ratio of -0.07 and a beta of 0.87. Aptose Biosciences has a 12-month low of $0.13 and a 12-month high of $2.20.

Hedge Funds Weigh In On Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC bought a new position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned approximately 9.46% of Aptose Biosciences at the end of the most recent quarter. 26.62% of the stock is currently owned by institutional investors.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.